KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Short term Debt (2017 - 2020)

Xenon Pharmaceuticals (XENE) has disclosed Short term Debt for 4 consecutive years, with $15.7 million as the latest value for Q1 2020.

  • On a quarterly basis, Short term Debt changed N/A to $15.7 million in Q1 2020 year-over-year; TTM through Mar 2020 was $15.7 million, a N/A change, with the full-year FY2019 number at $4.6 million, changed N/A from a year prior.
  • Short term Debt was $15.7 million for Q1 2020 at Xenon Pharmaceuticals, up from $4.6 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $15.7 million in Q1 2020 to a low of $700000.0 in Q4 2017.
  • A 4-year average of $4.7 million and a median of $2.8 million in 2019 define the central range for Short term Debt.